Ophthalmology

oph

Retinal Fibrosis

Diseases of the eye are well suited to therapeutic intervention using sd-rxRNA compounds. Local administration to the eye is an accepted method of administration and generally avoids systemic exposure. The use of sd-rxRNAs may change the landscape of ocular oligonucleotide-based therapeutics, enabling rapid discovery and validation of a wide range of novel therapeutic targets and creating the potential for next generation therapeutics for the treatment of serious ocular disorders. RXi’s sd-rxRNA technology is particularly well-suited this therapeutic area, having improved cellular uptake compared to ‘standard’ siRNAs and potent silencing activity. A clinical trial is ongoing to evaluate the safety and clinical activity of RXI-109 to prevent the progression of retinal scarring, a harmful component of numerous retinal diseases.

young eyes

Corneal Scarring

Corneal scarring refers to an injury of the cornea of the eye that causes opacity and visual impairment. The effects of corneal scarring can vary from blurring to blindness in the eye. Diseases of the eye are well suited to therapeutic intervention using sd-rxRNA compounds.  Local administration to the eye is an accepted method of administration and generally avoids systemic exposure.  RXi’s sd-rxRNA technology is particularly well-suited for this therapeutic area, having improved cellular uptake compared to ‘standard’ siRNAs and potent silencing activity.  RXi is involved in a number of collaborations to develop topical delivery for disorders of the cornea.